Hanson Wade

Are you aware of the biopharma and drug delivery leaders attending the 5th Ophthalmic Drug Delivery Summit this January in San Francisco? The meeting will bring together senior decision-makers across ocular drug delivery and development to address the practical challenges of advancing long-acting therapies, validating translational models, navigating regulatory expectations and accelerating next-generation ocular drug delivery technologies. We already have Noxilizer and Helbling confirmed as event partners, alongside a strong speaker faculty featuring organizations such as Genentech, Eli Lilly, Ripple Therapeutics and GelMEDIX. With %COMPANYNAME%'s work in the field, I wondered if this meeting would be of interest to you?

As in vivo innovations continue to expand, and breakthrough approvals reignite confidence in solid tumours, cell therapy stands on the cusp of a new chapter defined not just by possibility but clinical validation. Returning to London for its 10th anniversary, the CAR-TCR Europe Summit brings together Europe's leading CAR-T, TCR and cell therapy pioneers to explore the scientific, clinical and manufacturing strategies shaping the next generation of progress. View your copy of the 2027 brochure here: https://ter.li/7o4lsnt9

2026 may be remembered as the year amylin became a major therapeutic class. As billion-dollar deals, Phase II/III readouts, and increasing pharma investment accelerate competition, the key question is no longer whether amylin works, it's how to build the best asset. That's why academic KOLs including Thomas Lutz, Debbie Hay, Augen Pioszak alongside industry leaders from Novo, Eli Lilly, Zealand Pharma and more are gathering at the inaugural and only Amylin-Based Therapeutics Summit. Join peers across preclinical, translational, clinical and obesity R&D to debate: • Selective vs broad receptor targeting •Translating clinical outcomes back into biology • Defining the optimal amylin patient • Building best-in-class therapies Will you join your peers this December? For more information, view the full event guide: https://lnkd.in/dWQgmm5b

As radiopharmaceutical pipelines continue to expand, competitive advantage is increasingly being determined long before the clinic. The 3rd TRP Target Selection & Drug Design Summit is the only industry-focused meeting dedicated exclusively to the discovery and preclinical challenges of radiopharmaceutical target selection and drug design. Join the scientists responsible for identifying novel targets, selecting isotopes, optimizing targeting moieties, and designing the next generation of differentiated radiopharmaceuticals. Connect with experts across Discovery, Biology, Medicinal Chemistry, Radiochemistry, ADME/DMPK, Toxicology, Radiobiology, and Dosimetry to uncover the strategies shaping tomorrow's RLT pipelines. 👉 Explore the Agenda & Register: https://ter.li/oz7q13m9

The RNAi field is entering an exciting new phase, with breakthroughs in extrahepatic delivery unlocking opportunities across obesity, cardiovascular disease, CNS disorders, oncology, kidney disease, and retinal applications. Join 90+ RNAi leaders this January in Boston to explore the latest advances in delivery technologies, oligonucleotide chemistry, translational science, and clinical development. Connect with the companies and experts shaping the future of RNAi therapeutics and discover strategies to accelerate your own pipeline. 👉 View the full agenda and secure your place: https://ter.li/n7bx3o7e

The event that helped shape Europe's radiopharma community is back! Join the industry's leading targeted radiopharmaceutical developers to exchange insights, tackle critical development challenges, and accelerate the delivery of next-generation RLTs. ✅ Industry-leading case studies ✅Unrivalled networking opportunities ✅ Actionable strategies for successful development and scale-up Be part of the conversations driving the future of radiopharmaceutical innovation. Explore the full Event Guide here: https://ter.li/x4lmeubf